MEDP Stock Recent News

The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Medpace (MEDP) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.05 per share a year ago.

Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2023 financial results after the market close on Monday, October 23, 2023. The Company will host a conference call the following morning, Tuesday, October 24, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo.

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Medpace is a Contract Research Organization (CRO) that provides outsourced clinical development services to the biotech, pharma, and medical device industries. The business model is simpler than it seems and has shown great resilience in complicated macroeconomic environments. Although the current valuation is not attractive enough, Medpace seems like a must to add to any watchlist.